Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04880863
Status:
COMPLETED
Last Update Posted:
2024-02-22
First Post:
2021-05-03
Brief Title:
Naptumomab Estafenatox NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Sponsor:
NeoTX Therapeutics Ltd
Organization:
NeoTX Therapeutics Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-26
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-01-30
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-03
First Submit QC Date:
May 5 2021
Study First Post Date:
2021-05-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-21
Last Update Post Date:
2024-02-22
Last Update Post Date Type:
ACTUAL